Summary The p16 (MTS1) tumour-suppressor gene is a cyclin-dependent kinase (cdk) inhibitor that decelerates the cell cycle by inactivating the cdks that phosphorylate the retinoblastoma tumour-suppressor gene (Rb) protein (pRb). In cervical cancers, pRb is inactivated by the HPV E7 oncoprotein or by mutations. The hypothesis of earlier reports was that the disruption of the p16/cdk-cyclin/Rb cascade is essential for malignant cervical transformation/carcinogenesis. We previously established in vitro model systems of cervical cancer representing four steps of oncogenic progression initiated by the two most common oncogenic HPVs in ectocervical and endocervical epithelial cells. This report used these systems to investigate the role of p16 in cervical cancers. A dramatic enhancement of the p16 RNA level was observed after immortalization by HPV 16 or 18. Furthermore, the p16 protein was newly observed following immortalization. However, no further changes were found for RNA or protein levels after serum selection or malignant transformation. For three cervical carcinoma cell lines, similar high levels of p16 expression were seen. Point mutations or homozygous deletions of p16 were not observed in the in vitro systems or in clinical specimens. These results suggest that the inactivation of the p16/cdk-cyclin/Rb cascade does not occur during malignant transformation but occurs during the immortalization by HPV in HPV-harbouring premalignant lesions, the in situ equivalent of immortalized cells. Also suggested is that p16 has no role in the specific malignant transformation step from immortal premalignant lesions during the carcinogenesis of HPV-initiated cervical cancers.
Eukaryotic cell division is regulated by a series of protein kinase complexes consisting of cycin-dependent kinase (cdk) catalytic units and cyclin control units (Liu et al, 1995; reviewed in Kamb, 1995; Weinberg, 1995) . Furthermore, several cyclin-dependent kinase inhibitors have been identified as the control system that prevents the progression of the cell cycle. Examples are p21WAFI (El-Deiry et al, 1993; Gu et al, 1993; Xiong et al, 1993; Noda et al, 1994) , p27 (Polyak et al, 1994; Toyoshiba and Hunter, 1994) , p15 (Hannon and Beach, 1994) and p18 (Guan et al, 1994) . The deregulation of the cell cycle was proposed as an important mechanism for the malignant transformation of normal cells (Pardee, 1989) . For several kinds of cancers, the contribution of mutations in the sequences of the pl6 (M7TS) tumour-suppressor gene to the process of the carcinogenesis was proposed. Then, a number of studies showed that point mutations and homozygous deletions of p16 for some types of cancers and cancer cell lines were frequent (Caldas et al, 1994; Guan et al, 1994; reviewed in Kamb, 1995; Liu et al, 1995) . However, alterations of p16 were reported to be rare events in some cancers and tumour cell lines (Beltinger et al, 1995; Liu et al, 1995; Quesnel et al, 1995) , including cervical carcinomas and cell lines (Kelley et al, 1995; Hirama et al, 1996) . Therefore, the significance of p16 in the evolution of cervical cancer remains uncertain.
Cervical cancer is the most frequent cancer of the female genital tract. Cervical carcinogenesis has been studied extensively by various approaches, which firmly established the significance of infections by the oncogenic human papillomaviruses (HPVs) as initiators for the early stages (zur Hausen, 1994 ; zur Hausen and de Villiers, 1994) . The role played by promoting cofactor(s) in the later steps of progression to cervical malignancy following initiation remains uncertain, although many candidates are proposed (Herrington, 1995) .
Previously, we developed in vitro model systems for cervical cancer. The systems were derived from: the human ectocervix that supports infection; the endocervical origin of most cancers ; cells immortalized by HPV 16 and 18 that resemble premalignant lesions Yokoyama et al, 1994) ; immortalized cells adapted to serum that are propagated using the culture conditions used for cervical carcinoma cells (Nakao et al, 1996) ; and cells malignantly transformed by treatment with cigarette smoke condensate (CSC), an HPV co-factor (Yang et al, 1996a; Nakao et al, 1996) . The four stages of malignant progression were proposed to represent the in vivo equivalents in the multistep carcinogenesis of cervical cancer. In this report, we examined the RNA, protein and DNA of the important cellular p16 gene for the effects on transformation in our in vitro systems. For comparison, the status of p16 was assessed in biopsies of normal tissues, premalignant lesions and tumours from the cervix.
MM Pater passed away on 2 November 1994. p16 in HPV immortalization and tumorigenesis 1411 Table 1 Description of cells and cell lines   Cells  HPVa   Serumb  Tumorigenicityc   HEN  --NT  HEC  --NT  HEN-16  16  --HEN-16S  16  +  -HEN-16T  16  +  +  HEN-16-2  16  --HEN-16-2S  16  +  -HEN-16-2T  16  +  +  HEC-18-1  18  --HEC-18-1S  18  +  -HEC-18-1CT  18 
MATERIALS AND METHODS Cells and cell culture
The cells used in this study are described in Table 1 . One series of the stages of carcinogenesis was represented by primary human ectocervical cells (HEC), HPV 18-immortalized HEC (HEC-18-1), serum-adapted HEC-1 8-1 (HEC-18-1 S) and CSC-transformed HEC-18-1 (HEC-18-ICT). The series was established and cultured as described previously (Nakao et al, 1996) . Primary human endocervical cells (HEN), HPV 16-immortalized HEN (HEN-16) and another type of HPV 16-immortalized HEN (HEN-16-2) were established and cultured as described previously . Fetal calf serum-adapted HEN-16 (HEN-16S) and HEN-16-2 (HEN-16-2S) were initiated and cultured as described previously for HEC-18-1S (Nakao et al, 1996) . All three types of serum-adapted.cells were non-tumorigenic on nude mice. Malignantly transformed HEN-16 (HEN-16T) and HEN-16-2 (HEN-16-2T) were established and cultured as described previously (Yang et al, 1996a (Koffa et al, 1995 Northern blot RNA analysis Total cellular RNA was prepared and analysed using Northern blot assays as described previously (Yang et al, 1996b Tables 1 and  2 . The three primer pairs are described in Table 3 and were designed previously (Zhang et al, 1994) . One pair is for the analysis of p16 exon 1 and the other two pairs are for partly overlapping regions of most of exon 2. Two paraffin-embedded 8-gm slices were extracted as described previously (Koffa et al, 1995) .
Genomic DNA (50 ng) was amplified in the presence of I jCi [33P] dCTP (New England Nuclear) . PCR was as follows: 94°C for 2 min; 40 cycles of 94°C for 1 min and 62°C for 1 min; 72°C for 1 min; and 6 min at 72°C. PCR-amplified DNA was resolved in 6% polyacrylamide sequencing gels at 4°C. The gels were dried without fixation and exposed to Kodak XAR film for 12-72 h. The PCR amplification was repeated twice or more, and the results were consistent.
HPV typing
The PCR non-radioactive HPV detection system used HPV LI open reading frame consensus primers as described previously (Yoshikawa et al, 1991) with some modifications. The system was designed for highly sensitive and reliable screening and typing of HPVs contained in clinical samples. This system can identify a minimum of nine genital HPV types, HPV 6, 11, 16, 18, 31, 33, 42, 52 and 58. Amplification of 50 ng of DNA from paraffinembedded tissue was as follows: 94°C for 2 min; 40 cycles of 94°C for 1 min, 48°C for 1 min and 72°C for 2 min; and 6 min at 72°C. Electrophoresis of amplified DNA was in 1.5-3% agarose 1412 Y Nakao et al Table 3 Sequence and experimental design of primers Sequence Experimental design p16 El -sense, 5'-GCTGCGGAGAGGGGGAGAGCAGGCA-3' SSCPa for exon 1 p16 El -antisense, 5'-GCGCTACCTGATTCCMTTC-3' SSCP for exon 1 p1 6 E2-1 -sense, 5'-ACAAGCTTCCTTTCCGTCATGCCG-3' SSCP for exon 2-1 p16 E2-1-antisense, 5'-CCAGGCATCGCGCACGTCCA-3' SSCP for exon 2-1 pl 6 E2-2-sense, 5'-TTCCTGGACACGCTGGTGGT-3' SSCP for exon 2-2 p16 E2-2-antisense, 5'-TCTGAGCTTTGGAAGCTCTCAG-3' SSCP for exon 2-2 HPV Li-sense, 5'-CGTAAACGTTTTCCCTAT T -3'
HPV screening HPV HPV screening GAPDH-sense, 5'-AGTACGCTGCAGGGCCTCACTCCTT-3'
Control for DNA quality GAPDH-antisense, 5'-AAGAGCCAGTCTCTGGCCCCAGCCA-3'
Control for DNA quality aSSCP, single-strand conformation polymorphism. (Rossi and Hirschhorn, 1991) . In addition, the cells served as controls for the effect of the growth conditions used in generating and propagating the tumorigenic cells representing the final fourth stage in malignant progression. Relative to the actin control, no effects of serum selection were seen. More importantly, tumorigenic cells malignantly transformed by the HPV cofactor in cervical carcinogenesis, CSC, were examined. Compared with the other two stages of HPV-immortalized cells, they showed no significant alteration in the level of transcription. Again, this result applied to the three lines, both HPVs and two different cervical cell types. To test the relevance to naturally occurring cervical cancer, the established cervical carcinoma cell lines C33A, CaSki and HeLa were examined. All three showed the same high expression level of the p16 tumour-suppressor gene as the three stages of HPV-immortalized cells. These levels were much higher than for HEC and HEN (Figure lA and B) .
Level of p16 protein in in vitro model
To test the possible effect of post-transcriptional or translational regulation of p16, we used Western blot analysis with same model systems for malignant progression. The expression pattern of p16 protein was consistent with the results of mRNA expression. In comparison with the HEN human primary endocervical cells ( Figure 2A ) and HEC ectocervical parental cells (Figure 2B ), the expression of p16 was enhanced in the HPV 16-and 18-immortalized cells. The level of expression was stable during the final three steps of carcinogenesis of the HPV-immortalized cells, regardless of the changes that occurred during serum adaptation and tumorigenesis (Yang et al, 1996a; Nakao et al, 1996) . The three lines of established cervical cancer cells showed high expression levels of p16, protein levels consistent with those of our experimental model systems (Figure 2 ). (Figure 3 ; Kelley et al, 1995; Hirama et al, 1996) . (18) or absence of HPV (-) is indicated below the lanes. Other labels are described in the text p16 functions as a negative regulator of the cell cycle in the presence of wild-type Rb through the pl6/cdk-cyclin/Rb cascade (Guan et al, 1994; Lukas et al, 1995) . In cells containing an inactivated Rb or harbouring specific DNA tumour viruses, E2F is not sequestered by Rb, resulting in uncontrolled cell growth Whitaker et al, 1995; Yeager et al, 1995) . Furthermore, wild-type pRb down-regulated the promoter of p16, whereas the negative feedback by low levels of p16 enhanced p16 expression in Rb-inactivated, HPV-positive cells . Recently, the expression of p16 was found to be inversely correlated with pRb and Bcl-2 in cancer cell lines and cancers (Otterson et al, 1994; Nakamura et al, 1996; Sakaguchi et al, 1996) . For example, the C33A used in this study have no functional Rb. The results with p16 indicate the importance of p16 to the in vivo condition. The overexpression of p16 was observed in HPV-positive cell lines and cell lines expressing mutant Rb (Tam et al, 1994; Aagaard et al, 1995) . Although it would be of further interest to test p16 expression in cervical tumour, these data are consistent with the hypothesis that pl6 expression and function are dependent on Rb.
Point mutations in cervical samples
In cervical carcinogenesis, most cancers contain oncogenic HPV DNA (Bosch et al, 1995) . In vitro, the expression of viral E7 was necessary for transformation (von Knebel-Doeberitz et al, 1988) . E7 binds and inactivates pRb. The introduction of HPV during cervical cancer development apparently acted on the pl6/cdk-cyclin/Rb cascade by inactivating pRb, the p16 downstream alternate target. However, it was unknown whether changes during tumorigenesis were involved. Our in vitro model systems suggest that the inactivation of pRb by HPV E7 occurred in the initial immortalization step of oncogenesis. Consistently, no changes in levels of HPV mRNA were found during tumorigenesis in these systems previously (Nakao et al, 1996; Sarma et al, 1996) .-No changes in expression level or genetic alterations of pl6 were suggested to be involved in tumorigenesis after immortalization. This hypothesis is consistent with previous reports that genetic alterations of p16 were rarely seen in HPV-harbouring cervical carcinoma cell lines and HPV-negative cell lines that contain mutant Rb (Kelley et al, 1995; Hirama et al, 1996) . representing metaplastic and normal cervical tissues respectively. Next, the HPV 16-or HPV 18-immortalized human cervical cells and serum-adapted cells represent the continuum of progression to high-grade squamous intraepithelial lesions (HGSILs). Finally, the malignantly transformed cells represent cervical tumours. The advantages of these systems in investigating multistep carcinogenesis are: (1) the origins of the immortalized cells are clearly defined and distinct -each cell line was clearly endocervical or ectocervical in origin Sun et al, 1993; Yokoyama et al, 1994) ; (2) immortalized cells were derived with the two HPVs most frequently associated with the initiation of cervical oncogenesis (zur Hausen, 1994) ; (3) malignant clones were derived by treatment with CSC -cigarette smoking was proposed as an environmental cofactor of HPV, based on epidemiological and molecular biological studies (Herrington, 1995) .
Therefore the transformation of HPV-immortalized cervical cells by CSC is relevant to the in vivo situation and provides a suitable in vitro model for cervical cancer (Sarma et al, 1996; Yang et al, 1996a, b) ; and (4) the clinical lesions are relevant for the reasons stated below. Previously, we reported differential oncogenic potentials for our model systems with the in vitro organotypic (raft) culture and in vivo implantation differentiation systems. HPV-immortalized endocervical cells reconstructed into HGSILlike lesions, and HPV-immortalized ectocervical cells showed low-grade SIL (LGSIL)-like lesions in the two differentiation systems. Cells malignantly transformed by CSC resembled HGSIL-invasive squamous cell carcinomas in the in vitro differentiation system and were tumorigenic on nude mice (Nakao et al, 1996; Yang et al, 1996a) . These results show that HPV-immortalized cells correspond to LGSIL-HGSILs Tsutsumi et al, 1992; Yokoyama et al, 1994; Nakao et al, 1996; Yang et al, 1996a) . Because of these four reasons above, our systems are attractive for studying the progressive stages of cervical cancer.
The role ofp16 as a tumour-suppressor gene remains controversial at present. Tumour-suppressor genes can act in early or late stages of carcinoma development (reviewed by Vogelstein and Kinzler, 1993) . The roles of HPV E6 and E7 in inactivation of p53 and pRb tumour suppressors are required but not sufficient. For example, p53 deletions are seen in both HPV-positive and -negative cervical cancer (Mullokandov et al, 1996) . Thus, the role of pRb in senescence control may not have been its only role. Our experiments support the previous finding that mutations of p16 infrequently disrupt the pl6/cdk-cyclin/Rb cascade for the transformation that leads to cervical cancer (Kelley et al, 1995; Hirama et al, 1996) . Enhanced expression of p16 was observed in the initial immortalization step by HPV. Furthermore, our studies in the in vitro systems indicated that no inactivation of the pl6/cdkcyclin/Rb cascade occurs during the serum adaptation and tumorigenesis of HPV-immortalized cells. This cascade was apparently inactivated by the introduction of HPV but was insufficient for progression to the malignant transformation stage. Consistently, previous results suggested that p16 did not contribute to tumorigenesis, as alterations of this gene were already present in nontumorigenic immortalized breast epithelial cells (Cairms et al, 1994; Spruck et al, 1994; Brenner and Aldaz, 1995) .
In cytogenetic studies of cervical cancer, high-frequency loss of heterozygosity (LOH) and deletion of chromosomes 1, 3, 4, 5, 6, 10, 11, 17, 18 and X was reported (Sreekantaiah et al, 1988; Yokota et al, 1989; Mitra et al, 1994) . A recent small-scale study found LOH of the 9p21 locus to which pl6 is mapped in 20% of cervical cancer cases (Cairns et al, 1995 (Friedman et al, 1994) . Also, events occurring downstream of the p16 DNA may be involved in the altered expression levels. Expression was unaltered following tumorigenesis by CSC. Consistently, no published reports have associated cancers that are promoted by smoke with the expression of p16. Apparently, the dysregulation of the cell cycle by p16 is not the final step in progression to malignancy. Therefore, our results showing increased levels of RNA and protein expression following immortalization are important for clarifying the possible mechanism of initiating events in the carcinogenesis of cervical cancer. The fact that no increase was shown following the ultimate tumorigenesis was also revealing.
In conclusion, we suggest that (a) genetic alterations of p16 are rare events in cervical carcinogenesis; (b) transcription of p16 is the level at which disruption of the pl6/cdk-cyclin/Rb cascade occurs; (c) the disruption occurs during HPV-mediated immortalization and HPV infection; (d) smoking is an additional cofactor that acts by mutating the host genome, probably in p16-independent mechanisms, although it is necessary for the full malignant transformation that results in cervical epithelial neoplasms.
